GIP and fatty liver disease: Other groups have explored the concept of GLP-1/GIP/glucagon triagonism to obtain extra benefits from adding the benefits of glucagon action (promotion of energy expenditure and amelioration of fatty liver disease) to the ‘twincretin’ effects of GLP-1 and GIP.